Please login to the form below

Not currently logged in

safety review

This page shows the latest safety review news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos close in on filing for Xeljanz rival

Gilead and Galapagos close in on filing for Xeljanz rival

We are particularly pleased with the results filgotinib shows on clinically meaningful endpoints such as clinical remission, ACR70 and radiographic progression, as well as with the encouraging safety profile.". ... A lot will depend on the labelling that

Latest news

More from news
Approximately 2 fully matching, plus 75 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    As AZ can attest, with Forxiga initially being turned down by the FDA and Onglyza under safety review to investigate any link to heart failure, the regulatory environment has been a ... tough one for oral diabetes drugs in recent years, with the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...